A Real-world, Observational study to evaluate the clinical effectiveness and resource use patterns of Ranibizumab treat & extend regimen in patients with Neovascular Age-Related Macular Degeneration
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms TERRA
- 29 Jun 2017 New trial record
- 01 Jun 2017 Results (n=145; data cut-off 15 Nov 2016) published in the Ophthalmology and Therapy